Advertisement

Topics

Biogen Idec and Elan Corporation, plc Company Profile

23:42 EDT 21st June 2018 | BioPortfolio

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients worldwide benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.


News Articles [451 Associated News Articles listed on BioPortfolio]

Creating an urgency to change. Mikael Nilsson, Director of Marketing Excellence, Biogen Idec

Of the 20 to 60 thousand thoughts we have per day only about 2% are new. Most of our thoughts are old thoughts and that tells us something about the challenge to change. During the eyeforpharma confe...

Coming In Tuesday's "The Pink Sheet" DAILY - Royalty Pharma Makes A Move For Elan

Royalty Pharma’s $11 per-share bid for Elan is too low, according to Elan’s management and industry analysts.

Briefing, PTV News: Feb 10, 2010

Briefing:Swine flu helps Sanofi Tysabri boosts BioGen Elan's expectations

wikifolio whispers p.m. zu Baumot Group, Innogy, Biogen Idec ...

Aktuelle Kommentare aus dem wikifolio-Universum. Mit Links zu den jeweiligen Depots, damit man sieht, wie erfolgreich die Kommentatoren mit ihren Einschätzungen sind und wie sich die genannten Inpu.....

Latest News From "The Pink Sheet" DAILY - Royalty Pharma Makes A Play For Elan

For Elan Investors, A Choice Between A Sure Thing Or A High-Risk Play

Biogen Inc.: Biogen Appoints Daniel Karp as EVP, Corporate Development

Seasoned executive brings strong track record of success leading licensing and M&A transactions CAMBRIDGE, Mass., May 31, 2018 (GLOBE NEWSWIRE) -- Biogen (http://www.biogen.com/) (Nasdaq:BIIB) ann...

PTV News: Sep 4, 2009

Top stories on September 4th, 2009: The weed that sealed a US$287m deal Shire gets FDA approval for ADHD drug Elan loses Biogen court case MabThera goes from strength to strength How pharma deals...

Biogen and Samsung Bioepis Agree to Settlement with AbbVie Allowing Commercialization of IMRALDI (Adalimumab Biosimilar) in Europe

Biogen expects to launch IMRALDI in Europe on October 16, 2018 Biogen will be the first company to offer biosimilars of all three major anti-TNF therapies in Europe Biogen Inc. (Nasdaq: BIIB) and ...

PubMed Articles [3 Associated PubMed Articles listed on BioPortfolio]

A Review on Clinical Pharmacokinetics, Pharmacodynamics, and pharmacogenomics of natalizumab: A Humanized Anti-α4 Integrin Monoclonal Antibody.

Natalizumab (Tysabri®, Biogen-Idec Inc., NAT), a humanized anti-α4 integrin monoclonal antibody, binds in both α4β1 (Very Late Antigen 4, VLA-4) and α4β7 (lymphocytes Peyer's patch adhesion mole...

Syntactic processing in music and language: Effects of interrupting auditory streams with alternating timbres.

Both music and language rely on the processing of spectral (pitch, timbre) and temporal (rhythm) information to create structure and meaning from incoming auditory streams. Previous behavioural result...

Water Quality Assessment of the Pardo River Basin, Brazil: A Multivariate Approach Using Limnological Parameters, Metal Concentrations and Indicator Bacteria.

Located in the southeast of Brazil, the Pardo River Basin has a large population and an economy focused on agriculture, with a strong predominance of the sugarcane agro-industry. The purpose of the st...

Clinical Trials [15 Associated Clinical Trials listed on BioPortfolio]

Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma

This is a Phase I/II open-label, dose-escalating study in patients with metastatic colorectal cancer. The objectives of the study are to obtain information on the safety of radiolabeled I...

Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma

The purpose of this study is to determine whether anti-CD80 monoclonal antibody (IDEC-114) is effective in the treatment of follicular B-cell non-Hodgkin's lymphoma. This drug has never b...

Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma

To determine what side effects and what clinical effect, if any, the administration of this investigational product, IDEC-114 in combination with Rituxan® [Rituxan® as a single agent is ...

ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.

The purpose of this study is to see if we can find a new way to test how certain Multiple Sclerosis (MS) medications work in the body and to better understand how the medicines change cert...

Pregnancy Exposure Registry for AVONEX

This is an observational, exposure-registration and follow-up study, which will be conducted in the United States (US). The AVONEX® Pregnancy Exposure Registry is designed to monitor pre...

Companies [222 Associated Companies listed on BioPortfolio]

Biogen Idec and Elan Corporation, plc

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufa...

Biogen Idec Inc.

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufa...

Elan Corporation, plc

Elan Corporation, plc is a neuroscience-based biotechnology company focused on discovering and developing advanced therapies in neurodegeneration and autoimmune diseases, and real...

Biogen Idec and Abbott

Biogen Idec uses cutting-edge science to discover, develop, manufacture and market therapies for serious diseases with a focus on neurology, immunology and hemophilia. Founded in ...

Biogen Idec and Portola Pharmaceuticals

Biogen Idec uses cutting-edge science to discover, develop, manufacture and market therapies for serious diseases with a focus on neurology, immunology and hemophilia. Founded in ...

More Information about "Biogen Idec and Elan Corporation, plc" on BioPortfolio

We have published hundreds of Biogen Idec and Elan Corporation, plc news stories on BioPortfolio along with dozens of Biogen Idec and Elan Corporation, plc Clinical Trials and PubMed Articles about Biogen Idec and Elan Corporation, plc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Biogen Idec and Elan Corporation, plc Companies in our database. You can also find out about relevant Biogen Idec and Elan Corporation, plc Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Orthopedics
Arthroplasty Joint Disorders Orthopedics Spinal Cord Disorders Orthopedics is the science or practice of correcting deformities caused by disease or damage to the bones and joints of the skeleton. This specialized branch of surgery may ...


Corporate Database Quicklinks



Searches Linking to this Company Record